16 February 2015 – fund raising/collaboration
The company has announced that it is to raise £8.8m (gross) through a fund raising with new and existing shareholders at a price of 65p. The funds raised will be used to help fund the continuing development programme at the group including the new collaboration with the MD Anderson Cancer Center at The University of Texas. The latter will investigate the clinical use of the group’s Parsortix system as a companion diagnostic in colorectal cancer. The group continues to develop well and we maintain our recommendation of BUY.